Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986507 Combinations in Advanced Solid Tumors
NCT06618287Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2025
- Primary completion
- Feb 2031
- Countries
- 10
01
Overview
Phase 2, open-label trial of izalontamab brengitecan in non-small cell lung cancer (NSCLC) and breast cancer (5 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Adverse Events at 3 years, Serious Adverse Events at 3 years and 3 more. Started Feb 2025; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
non-small cell lung cancer (NSCLC)breast cancer
Beyond the preview
Go deeper on NCT06618287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06618287.